APL is a state-owned Swedish company that provides compounding services and manufacturing of extemporaneous pharmaceutical preparations. It offers these services to community and hospital pharmacies through agreements. APL also provides contract development and manufacturing services to life science companies. Previously in Sweden, compounding was centralized through APL, but market deregulation led to competition among multiple providers of compounding services. Hospital pharmacies are now contracted through competitive tender processes set by regional healthcare authorities. This has resulted in both benefits like innovation and cost savings through competition, but also challenges like potential cost-cutting, lack of national overview, and less collaboration between players.
EliT Medical - complex solutions for your laboratory robertbul
EliT Medical (http://www.elitmedical.com/aboutus_en.html ) is a private Bulgarian company, established beginning of 2002.
We have in our product list a well-balanced portfolio of reagents and equipment, offering a complete solution for every clinical lab.
We offer to our customers and partners complex solutions and are focusing on providing problem-free and secure functioning of the customers’ lab.
EliT Medical is offering a complete consultancy services. Our team has a long market experience and the very good knowledge of the products in the diagnostics laboratory field. This is the base for us to provide our customers with decisions, that will help them organize their labs and activities in the most efficient, competitive and profitable way, will help them to offer their patients the most modern and effective diagnostics and fast and accurate results. We can help in the complete process –planning, establishing, equipping, organization and functioning of the diagnostic laboratory.
The products are of outstanding quality, manufactured by world-leading companies from Austria, Ireland, Japan, Poland, Switzerland, the USA etc.
We carefully chose and select our suppliers and partners, because for us the premium quality of the offered products and the satisfaction of our customers if the first priority in our everyday business.
Our company aim is to improve continuously the quality of our work at more competitive price levels. This, together with our already build relations and leading market position are the premises for the attractive prices and customers oriented policy, which we are able to offer.
Our portfolio includes a complex equipment, reagents and consumables for clinical laboratories in hospitals, laboratory-diagnostic units and private medical centers. We offer fully automated biochemical and clinical chemistry diagnostic systems; automated immunological analyzers; automatic 3-diff and 5-diff hematology instruments; automated systems for ion-selective analysis; semi-automatic and automatic instruments for coagulation; instruments and tests for POC and express diagnostics, etc., as well as high quality diagnostic reagents, quality test tubes for closed blood collection system, consumables, spare parts and full servicing for the installed equipment. Our clinical chemistry portfolio includes a full range of routine and sophisticated analyzers covering the complete range – from small – medium to high capacity instruments, also able to perform immunochemistry tests essential for accurate diagnosis. For haematology lab, we provide an innovative technology for the most popular 3-Diff and advanced 5-Diff systems supported by Swiss analyzers.
We also offer general lab equipment as centrifuges and microscopes from premium European producers.
You can be among our friends and partners!
EliT Medical - complex solutions for your laboratory robertbul
EliT Medical (http://www.elitmedical.com/aboutus_en.html ) is a private Bulgarian company, established beginning of 2002.
We have in our product list a well-balanced portfolio of reagents and equipment, offering a complete solution for every clinical lab.
We offer to our customers and partners complex solutions and are focusing on providing problem-free and secure functioning of the customers’ lab.
EliT Medical is offering a complete consultancy services. Our team has a long market experience and the very good knowledge of the products in the diagnostics laboratory field. This is the base for us to provide our customers with decisions, that will help them organize their labs and activities in the most efficient, competitive and profitable way, will help them to offer their patients the most modern and effective diagnostics and fast and accurate results. We can help in the complete process –planning, establishing, equipping, organization and functioning of the diagnostic laboratory.
The products are of outstanding quality, manufactured by world-leading companies from Austria, Ireland, Japan, Poland, Switzerland, the USA etc.
We carefully chose and select our suppliers and partners, because for us the premium quality of the offered products and the satisfaction of our customers if the first priority in our everyday business.
Our company aim is to improve continuously the quality of our work at more competitive price levels. This, together with our already build relations and leading market position are the premises for the attractive prices and customers oriented policy, which we are able to offer.
Our portfolio includes a complex equipment, reagents and consumables for clinical laboratories in hospitals, laboratory-diagnostic units and private medical centers. We offer fully automated biochemical and clinical chemistry diagnostic systems; automated immunological analyzers; automatic 3-diff and 5-diff hematology instruments; automated systems for ion-selective analysis; semi-automatic and automatic instruments for coagulation; instruments and tests for POC and express diagnostics, etc., as well as high quality diagnostic reagents, quality test tubes for closed blood collection system, consumables, spare parts and full servicing for the installed equipment. Our clinical chemistry portfolio includes a full range of routine and sophisticated analyzers covering the complete range – from small – medium to high capacity instruments, also able to perform immunochemistry tests essential for accurate diagnosis. For haematology lab, we provide an innovative technology for the most popular 3-Diff and advanced 5-Diff systems supported by Swiss analyzers.
We also offer general lab equipment as centrifuges and microscopes from premium European producers.
You can be among our friends and partners!
Oriola-KD operates as an effective and reliable channel between pharmaceutical manufacturers and consumers in Northern Europe. Oriola-KD engages in pharmaceutical retailing, i.e. pharmacy operations, in Sweden, online pharmacy business in Latvia and pharmaceutical wholesaling and distribution in Finland, Sweden and the Baltic countries. In addition Oriola-KD markets health and well-being products in Finland and the Baltic countries. Oriola-KD’s net sales for 2014 were approximately EUR 1.6 billion. Company has approximately 2 350 employees. Oriola-KD is listed on NASDAQ OMX Helsinki Ltd.
Market report on the opportunities in the Norwegian healthcare market, prepared for the Team Finland Digital Hospitals growth program by Fintra in partnership with Oslo Medtech.
2016-11-28 Mentlife seminar: Pharmaceutical Drug Development; An Overall Pers...MentLife
This seminar provided an understanding of modern pharmaceutical drug development – the different phases of drug development and insight into different jobs.
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringeDanielle Labreche
Aguettant launches in Europe the first Sulphate Free EPINEPHRINE (Adrenaline) polypropylene Pre-Filled syringe
Individually blisterized - Sterile Field Ready - Luer Lock Connectivity (smPC available on demand)
ECO 11: Medicines Optimisation in Northern Ireland - Frans van AndelInnovation Agency
Frans introduces the work of the Medicines Optimisation Innovation Centre based in Northern Ireland. He talks about their background; aims and how they achieve them; and current key initiatives. Frans also discusses the ongoing work of MOIC in enabling technology, the pharmaceutical industry, knowledge transfer, training and education, and other key initiatives.
FASS - Presentation and discussion of Good Practice Example: MaliniakNowgen
"FASS - Presentation and discussion of Good Practice Example", presented by Ann Maliniak, Swedish Association of the Pharmaceutical Industry (LIF), Sweden, at EUPATI 2014 Workshop on 2 April 2014 in Warsaw
SPHS Webinar Series: Human Rights, Water and Antimicrobial Resistance: A New ...UN SPHS
In light of the discussions held at the Asia Forum 2018 Campfire Session led by Stockholm International Water Institute (SIWI), the SPHS webinar "Human Rights, Water and Antimicrobial Resistance: A New Nexus-Approach To Address a Complex Challenge?" focuses on the relationship between a healthy environment and human rights, with a special focus on water and antibiotics. Experts explain how this approach can stimulate virtuous developments within the health sector, and how health care providers ensure simultaneous access to affordable medicines while safeguarding human rights of people living nearby production sites, who share the same water resources. The objective is to share information with the audience about the activities of pharmaceutical companies and relevant stakeholders from the health sector, including leading practices and gaps, to trigger a conversation on how purchasers can influence sustainable procurement of pharmaceuticals.
In addition, Active Pharmaceutical Ingredients (APIs & Formulations) or chemicals that are discharged in the wastewater from the production of pharmaceuticals, impact the human health and the environment through water contamination. The webinar also discusses strategies to effectively measure and monitor the APIs in the wastewater discharged resulting from production, development and related activities involving pharmaceuticals manufacturing.
Oriola-KD operates as an effective and reliable channel between pharmaceutical manufacturers and consumers in Northern Europe. Oriola-KD engages in pharmaceutical retailing, i.e. pharmacy operations, in Sweden, online pharmacy business in Latvia and pharmaceutical wholesaling and distribution in Finland, Sweden and the Baltic countries. In addition Oriola-KD markets health and well-being products in Finland and the Baltic countries. Oriola-KD’s net sales for 2014 were approximately EUR 1.6 billion. Company has approximately 2 350 employees. Oriola-KD is listed on NASDAQ OMX Helsinki Ltd.
Market report on the opportunities in the Norwegian healthcare market, prepared for the Team Finland Digital Hospitals growth program by Fintra in partnership with Oslo Medtech.
2016-11-28 Mentlife seminar: Pharmaceutical Drug Development; An Overall Pers...MentLife
This seminar provided an understanding of modern pharmaceutical drug development – the different phases of drug development and insight into different jobs.
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringeDanielle Labreche
Aguettant launches in Europe the first Sulphate Free EPINEPHRINE (Adrenaline) polypropylene Pre-Filled syringe
Individually blisterized - Sterile Field Ready - Luer Lock Connectivity (smPC available on demand)
ECO 11: Medicines Optimisation in Northern Ireland - Frans van AndelInnovation Agency
Frans introduces the work of the Medicines Optimisation Innovation Centre based in Northern Ireland. He talks about their background; aims and how they achieve them; and current key initiatives. Frans also discusses the ongoing work of MOIC in enabling technology, the pharmaceutical industry, knowledge transfer, training and education, and other key initiatives.
FASS - Presentation and discussion of Good Practice Example: MaliniakNowgen
"FASS - Presentation and discussion of Good Practice Example", presented by Ann Maliniak, Swedish Association of the Pharmaceutical Industry (LIF), Sweden, at EUPATI 2014 Workshop on 2 April 2014 in Warsaw
SPHS Webinar Series: Human Rights, Water and Antimicrobial Resistance: A New ...UN SPHS
In light of the discussions held at the Asia Forum 2018 Campfire Session led by Stockholm International Water Institute (SIWI), the SPHS webinar "Human Rights, Water and Antimicrobial Resistance: A New Nexus-Approach To Address a Complex Challenge?" focuses on the relationship between a healthy environment and human rights, with a special focus on water and antibiotics. Experts explain how this approach can stimulate virtuous developments within the health sector, and how health care providers ensure simultaneous access to affordable medicines while safeguarding human rights of people living nearby production sites, who share the same water resources. The objective is to share information with the audience about the activities of pharmaceutical companies and relevant stakeholders from the health sector, including leading practices and gaps, to trigger a conversation on how purchasers can influence sustainable procurement of pharmaceuticals.
In addition, Active Pharmaceutical Ingredients (APIs & Formulations) or chemicals that are discharged in the wastewater from the production of pharmaceuticals, impact the human health and the environment through water contamination. The webinar also discusses strategies to effectively measure and monitor the APIs in the wastewater discharged resulting from production, development and related activities involving pharmaceuticals manufacturing.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
that.pptx
1. Disclosure
Eva Sjökvist Saers, CEO of APL
Apotek Produktion & Laboratorier AB
• APL is a state-owned company and a national centre of excellence for
compounded pharmaceuticals.
• APL is a “extempore pharmacy”, with license from MPA, that offers
compounding services (development and manufacturing of extemporaneous
preparations and stock preparations) to community and hospital pharmacies,
either directly according to agreements as a part of the hospital
pharmacy or as a subcontractor.
• APL offers its services according to equal and non-discriminating
conditions, as an assignment from the government.
• The compounding sector is today on a competitive market
• APL is also a CDMO (Contract Development and Manufacturing
Organisation) that offers development and manufacturing services to
companies within Life Science.
EAHP 2014 - Eva Sjökvist Saers, Sweden
2. To move from one model to another
Re-regulation of the pharmacy market in Sweden –
consequences on the hospital pharmacies with
focus on compounding
EAHP 2014 - Eva Sjökvist Saers, Sweden
3. Re-regulation of the pharmacy market in Sweden –
consequences on the hospital pharmacies
• Until 2009/2010 the state-owned company Apoteket had
the exclusive right to sell drugs in Sweden – community
and hospital pharmacies
• All hospital pharmacies were run by Apoteket, on behalf
of each county council according to agreements.
• Preparations of cytotoxics and sterile individual
preparations were made at the hospital pharmacies
• Compounding (extemporaneous preparations, stock
preparations) was centralised to the four production units of
APL (earlier subsidiary to Apoteket)
• One national process owner for the
”manufacturing/compounding process” at Apoteket/APL
EAHP 2014 - Eva Sjökvist Saers, Sweden
Earlier model
4. • > 10.000 compositions in data base
• ~ 2.000 compositions manufactured frequently
• About 300 stock preparations, of which 140 with a national
license from MPA
• Therapeutic areas e.g.:
- Pediatrics
- Pain
- Dermatology
- Dental care
- Cardiovascular
- Stomach/intestine
- Eyes/ear
- Gynecology
- Urology
- Veterinary
EAHP 2014 - Eva Sjökvist Saers, Sweden
APL’s extemporaneous pharmaceuticals
6. APL large scale manufacturing of stock preparations
and extemporaneous manufacturing
EAHP 2014 - Eva Sjökvist Saers, Sweden
Stockholm
Solid preparations
Clinical trials materials
Pharmaceutical/Analytical development
APL Customer Services
Extemporaneous pharmaceuticals
Umeå
Sterile and aseptic manufacturing
Clinical trials materials
Malmö
Non-sterile manufacturing
Semi solids
Göteborg
Non-sterile manufacturing
Oral solutions
Supply Chain & Logistics
Extemporaneous pharmaceuticals
Preparation at hospitals (tender)
West Sweden: Varberg, Sahlgrenska, Östra, Uddevalla, Skövde, Borås
Stockholm: Solna and Stockholm
7. Development of individualised medicines for
patients with special needs
APL Customer Services
Product range specialist
Formulation specialist
Procurement/Logistics
Extemporaneous
preparations/Stock preparations
Supply
Individualised
medicines
Medical Products
Agency (MPA)
EAHP 2014 - Eva Sjökvist Saers, Sweden
8. Health care at hospitals in Sweden
• At the regional level, responsibility
for financing and providing health
care is decentralized to the county
councils (regions).
• 21 regions are responsible for the
organisation and management of
health care at the hospitals in
each region
• Hospital pharmacy management –
procurement process with strict
requirements. The requirements
are set by the respective regions.
• Only one region manages the
hospital pharmacies
in-house (Jönköping)
EAHP 2014 - Eva Sjökvist Saers, Sweden
Stockholm
Gothenburg
Malmö
Current model
10. Requirement specifications (no of mandatory claims)
Tender in Stockholm county council for extemporaneous manufacturing
• Tender invitation (general
claims 34)
• Assignment (4)
• Organisation (23)
• Quality management (11)
• Supply of goods (22)
• Ordering process (29)
• Distribution (23)
EAHP 2014 - Eva Sjökvist Saers, Sweden
• Supply reliability (3)
• Opening hours and
avaliability (7)
• Monitoring (4)
• Principles for pricing (8)
• Clinical trial materials (5)
• Environmental issues (2)
• Performance (14)
• Approx. 190 mandatory
claims
11. Contractors to date
Service Apoteket** APL* Apotek
Hjärtat**
ApoEx Unimedic* Region
Jönköping
(in-house)
A. Drug supply X - X X - X
B. Pharma-
ceutical
services
X - X X - X
C. Extemporaneous preparations
- Cytotoxics X X X - - X
- Sterile
preparations
X X X - - X
- Individual
compounded
preparations
(sterile /
non sterile)
- X - - - -
- Stock
preparations
- X
approx 300
- - X
approx 15
-
EAHP 2014 - Eva Sjökvist Saers, Sweden
* extempore pharmacy ** pharmacy chain with community and hospital pharm.
12. Forum for national development of activities at
hospital pharmacies incl. extemporaneous
preparations
• Swedish Society of Pharmaceutical sciences
- Swedish Society of Hospital Pharmacy
Section for members from e.g. hospital pharmacies, county councils,
authorities
• Swedish Association of Local Authorities and Regions
Working group for pharmacists
employed by the county councils
EAHP 2014 - Eva Sjökvist Saers, Sweden
13. Some consequences of the current model
• Competition and diversity
drive innovation
• Competition lowers the
price
• A variety of services and
solutions available from
different providers
• Some issues become
more significant (IT,
logistics etc)
EAHP 2014 - Eva Sjökvist Saers, Sweden
• Fragmentation with less
overview
• Regional aspects rather
than national
• Cost cutting can lead to
less time for continous
training/education of staff
• Competition leads to less
openness between
players
14. Thanks to
Lars-Åke Söderlund
Swedish Society of Pharmaceutical sciences (board) /Apoteket
Sari Frigård
Swedish Society of Hospital Pharmacy (chairman) / Apoteket
Magnus Munge
Swedish Society of Hospital Pharmacy (board) /
County council of Kronoberg
Eva Einarsson
Apotek Hjärtat Business unit Health care
EAHP 2014 - Eva Sjökvist Saers, Sweden
15. Together we contribute to drugs
that improve and save lives!
We are proud of that!
EAHP 2014 - Eva Sjökvist Saers, Sweden
Thank you!
eva.sjokvistsaers@apl.se